Aroa Biosurgery Limited (ASX:ARX)
Australia · Delayed Price · Currency is AUD | Market Cap | 207.54M +33.7% |
| Revenue (ttm) | 79.26M +18.4% |
| Net Income | -1.60M |
| EPS | -0.00 |
| Shares Out | 345.90M |
| PE Ratio | n/a |
| Forward PE | 39.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,944 |
| Average Volume | 250,044 |
| Open | 0.6150 |
| Previous Close | 0.6200 |
| Day's Range | 0.6000 - 0.6150 |
| 52-Week Range | 0.4270 - 0.8000 |
| Beta | 0.83 |
| RSI | 51.00 |
| Earnings Date | May 26, 2026 |
About Aroa Biosurgery
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft... [Read more]
Financial Performance
In fiscal year 2025, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2024.
Financial numbers in NZD Financial StatementsNews
Aroa Biosurgery Earnings Call Transcript: Q3 2026
Clinical and commercial momentum is strong, with Myriad outperforming in trauma and Symphony poised to benefit from US reimbursement changes. FY26 revenue and EBITDA are tracking toward the upper end of guidance, with ongoing profitability and positive cash flow.
Aroa Biosurgery Earnings Call Transcript: H1 2026
Revenue grew 13% YoY to $44.9M with positive EBITDA and strong cash flow. Myriad sales surged 33%, and Tela Bio expanded its commercial team and product pipeline. CMS reimbursement changes may disrupt competitors, creating new opportunities.
Aroa Biosurgery Earnings Call Transcript: Q2 2026
Achieved a fourth consecutive quarter of positive cash flow, with record Myriad sales up over 30% year-over-year and strong cash reserves. Guidance for revenue and EBITDA was reiterated, while U.S. reimbursement changes and tariffs present manageable risks.
Aroa Biosurgery Transcript: AGM 2025
The meeting reviewed strong 23% growth, margin improvements, and positive cash flow, with continued investment in product development and international expansion. No dividend is planned as focus remains on reinvestment. Key risks include U.S. tariffs and TELA Bio's performance.
Aroa Biosurgery Earnings Call Transcript: Q1 2026
Sales and cash flow tracked in line with expectations, with strong Myriad and TELA Bio performance. Guidance for revenue and EBITDA was reaffirmed, and CMS reimbursement proposals could benefit Symphony if enacted.
Aroa Biosurgery Earnings Call Transcript: H2 2025
Revenue grew 23% to AUD 84.7 million, with first positive normalized EBITDA of AUD 4.2 million and strong cash position. Myriad drove growth, while guidance for FY 2026 targets 10–20% revenue increase and continued profitability.